Exploration of Medicine

From: High prevalence of false positive SARS-CoV2 serology in a cohort of patients with liver autoimmune diseases

Table 1. Baseline characteristics

Variable	N (%)
PBC	18 (42.85%)
AIH	12 (28.57%)
PBC/AIH overlap syndrome	12 (28.57%)
Positive RT-PCR	2 (4.76%)
Positive antigenic rapid test	2 (4.76%)
Positive serology	2 (4.76%)
False positive serology	14 (30.95%)
ANA positivity	28 (66.6%)
AMA positivity	16 (38.09%)
ANCA positivity	4 (9.52%)
ASMA positivity	12 (28.57%)
Anti-LKM positivity	2 (4.76%)
Variable	Mean ± SD
Direct bilirubin (mg/dL)	0.19 ± 0.17
Indirect bilirubin (mg/dL)	0.69 ± 0.36
GOT (U/L)	41.33 ± 21.48
GPT (U/L)	41.95 ± 23.48
GGT (U/L)	84.61 ± 85.45
ALP (U/L)	124.14 ± 58.67
CRP (mg/L)	4.06 ± 6.08
ESR (mm/h)	26.42 ± 21.61
Gamma globulin (%)	0.19 ± 0.07

Return to article view

GOT: glutamic-oxaloacetic transaminase; GPT: glutamic-pyruvic transaminase; ALP: alkaline phosphatase; ESR: erythrocyte sedimentation rate; ANA: antinuclear antibody; AMA: antimitochondrial antibodies; ANCA: anti-neutrophil cytoplasmic antibody; ASMA: anti-smooth muscle antibody; anti-LKM: anti–liver-kidney microsomal; GGT: gamma-glutamyltransferase; CRP: C-reactive protein

Declarations

Author contributions

MGC contributed to data collection, study design and paper draft; MS performed the analysis and contributed to study design and paper draft; RV, FC, GDG and PC organized the database and revised sections of the manuscript; GS conceptualized and supervised the entire work.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

All the procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Consent to participate

Informed consent to participate in the study was obtained from all participants.

Consent to publication

Not applicable.

Availability of data and materials

All relevant data is contained within the manuscript.

Funding

Not applicable.

Copyright

References

WHO Coronavirus (COVID-19) Dashboard [Internet]. World Health Organization. c2021 [cited 2021 Jun 11]. Available from: https://covid19.who.int/

Grant MC, Geoghegan L, Arbyn M, Mohammed Z, McGuinness L, Clarke E, et al. The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): a systematic review and meta-analysis of 148 studies from 9 countries. PloS One. 2020;15:e0234765 [DOI] [PubMed] [PMC]

Yüce M, Filiztekin E, Özkaya KG. COVID-19 diagnosis—a review of current methods. Biosens Bioelectron. 2021;172:112752. [DOI] [PubMed] [PMC]

Baumgarth N, Nikolich-Ž ugich J, Eun-Hyung Lee F, Bhattacharya D. Antibody responses to SARS-CoV-2: let’s stick to known knowns. J Immunol. 2020;205:2342–50. [DOI] [PubMed]

Winthrop KL, Chiller T. Preventing and treating biologic-associated opportunistic infections. Nat Rev Rheumatol. 2009;5:405–10. [DOI] [PubMed]

Dubin PJ, Kolls JK. Th17 cytokines and mucosal immunity. Immunol Rev. 2008;226:160–71. [DOI] [PubMed]

Whitman JD, Hiatt J, Mowery CT, Shy BR, Yu R, Yamamoto TN, et al. Evaluation of SARS-CoV-2 serology assays reveals a range of test performance. Nat Biotechnol. 2020;38:1174–83. [DOI] [PubMed]

Liberal R, Grant CR. Cirrhosis and autoimmune liver disease: current understanding. World J Hepatol. 2016;8:1157–68. [DOI] [PubMed] [PMC]

Kharlamova N, Dunn N, Bedri SK, Jerling S, Almgren M, Faustini F, et al. False positive results in SARS- CoV-2 serological tests for samples from patients with chronic inflammatory diseases. Front Immunol. 2021;12:666114. [DOI] [PubMed] [PMC]

10.

Teng J, Dai J, Su Y, Zhou Z, Chi H, Wan L, et al. Detection of IgM and IgG antibodies against SARS-CoV-2 in patients with autoimmune diseases. Lancet Rheumatol. 2020;2:e384–5. [DOI]

11.

Wang Y, Sun S, Shen H, Jiang L, Zhang M, Xiao D, et al. Cross-reaction of SARS-CoV antigen with autoantibodies in autoimmune diseases. Cell Mol Immunol. 2004;1:304–7. [PubMed]

12.

Wang Q, Du Q, Guo B, Mu D, Lu X, Ma Q, et al. A method to prevent SARS-CoV-2 IgM false positives in gold immunochromatography and enzyme-linked immunosorbent assays. J Clin. Microbiol. 2020;58:e00375–20. [DOI]

13.

Zouvelekis A, Karampitsakos T, Krompa A, Markozannes E, Bouros D. False positive COVID-19 antibody test in a case of granulomatosis with polyangiitis. Front Med (Lausanne). 2020;7:399. [DOI] [PubMed] [PMC]

14.

Vojdani A, Kharrazian D. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. Clin Immunol. 2020;217:108480. [DOI] [PubMed] [PMC]

15.

Marjot T, Buescher G, Sebode M, Barnes E, Sidney Barritt A 4th, Armstrong MJ, et al. SARS-CoV-2 infection in patients with autoimmune hepatitis. J Hepatol. 2021;74:1335–43. [DOI] [PubMed] [PMC]